StockNews.AI
THAR
StockNews.AI
105 days

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

1. Tharimmune released positive Phase 1 study data for TH104. 2. FDA feedback supports TH104's use for opioid-related respiratory depression.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive FDA feedback and advancement in clinical trials typically drive stock prices upward, especially in biotech.

How important is it?

The FDA's endorsement and study results could significantly enhance investor confidence and market performance.

Why Long Term?

Long-term effects are expected as TH104 progresses through further trials and potential market introduction.

Related Companies

NLMPDLIAXGN
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released pharmacokinetic and metabolism data from its Phase 1 study of TH104, a buccal film formulation of nalmefene, in healthy subjects. Tharimmune recently highlighted the advancement of TH104 for the proposed indication of temporary prophylaxis against respiratory and/or central nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids, following recent positive feedback from the U.S. Food and Drug Administration (FDA).

Related News